Next Article in Journal
Efficacy and Safety of OnabotulinumtoxinA 400 Units in Patients with Post-Stroke Upper Limb Spasticity: Final Report of a Randomized, Double-Blind, Placebo-Controlled Trial with an Open-Label Extension Phase
Next Article in Special Issue
Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis
Previous Article in Journal
Phytotoxic Metabolites Isolated from Neufusicoccum batangarum, the Causal Agent of the Scabby Canker of Cactus Pear (Opuntia ficus-indica L.)
Previous Article in Special Issue
Can Botulinum Toxin A Play a Role in Treatment of Chronic Pelvic Pain Syndrome in Female Patients?—Clinical and Animal Evidence
Open AccessReview

Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders

by Yu-Hua Lin 1,2,3, Bing-Juin Chiang 1,4,5 and Chun-Hou Liao 1,4,*
Divisions of Urology, Department of Surgery, Cardinal Tien Hospital, New Taipei City 23148, Taiwan
Department of Chemistry, Fu Jen Catholic University, New Taipei City 24205, Taiwan
Graduate Institute of Biochemical and Pharmaceutical Science, Fu Jen Catholic University, New Taipei City 24205, Taiwan
College of Medicine, Fu-Jen Catholic University, New Taipei City 24205, Taiwan
School of Life Science, College of Science, National Taiwan Normal University, Taipei 11677, Taiwan
Author to whom correspondence should be addressed.
Toxins 2020, 12(2), 129;
Received: 31 December 2019 / Revised: 3 February 2020 / Accepted: 14 February 2020 / Published: 18 February 2020
Intravesical botulinum toxin (BoNT) injection is effective in reducing urgency and urinary incontinence. It temporarily inhibits the detrusor muscle contraction by blocking the release of acetylcholine (Ach) from the preganglionic and postganglionic nerves in the efferent nerves. BoNT-A also blocks ATP release from purinergic efferent nerves in the detrusor muscle. In afferent nerves, BoNT-A injection markedly reduces the urothelial ATP release and increases nitric oxide (NO) release from the urothelium. BoNT-A injection in the urethra or bladder has been developed in the past few decades as the treatment method for detrusor sphincter dyssyndergia, incontinence due to neurogenic or idiopathic detrusor overactivity, sensory disorders, including bladder hypersensitivity, overactive bladder, and interstitial cystitis/chronic pelvic pain syndrome. Although the FDA only approved BoNT-A injection treatment for neurogenic detrusor overactivity and for refractory overactive bladder, emerging clinical trials have demonstrated the benefits of BoNT-A treatment in functional urological disorders. Cautious selection of patients and urodynamic evaluation for confirmation of diagnosis are crucial to maximize the successful outcomes of BoNT-A treatment. View Full-Text
Keywords: botulinum toxin; functional urology disorder; human botulinum toxin; functional urology disorder; human
MDPI and ACS Style

Lin, Y.-H.; Chiang, B.-J.; Liao, C.-H. Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders. Toxins 2020, 12, 129.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop